BioSyent Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOYF research report →
About the company
BioSyent Inc. , together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
- CEO
- René C. Goehrum
- IPO
- 2012
- Employees
- 711
- HQ
- Mississauga, ON, CA
Price Chart
- Market Cap
- $116.44M
- P/E
- 17.90
- P/S
- 3.61
- P/B
- 3.65
- EV/EBITDA
- 12.58
- Div Yield
- 1.45%
- Gross Margin
- 74.11%
- Op Margin
- 25.10%
- Net Margin
- 19.65%
- ROE
- 22.05%
- ROIC
- 17.03%
- Revenue
- $43.02M · 22.80%
- Net Income
- $9.00M · 23.86%
- EPS
- $0.80 · 25.00%
- Op Income
- $11.30M
- FCF YoY
- 139.31%
- 52W High
- $12.00
- 52W Low
- $7.63
- 50D MA
- $10.28
- 200D MA
- $9.61
- Beta
- 0.63
- Avg Volume
- 2.79K
Get TickerSpark's AI analysis on BIOYF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BIOYF coverage
Recent articles, reports, and earnings notes.
No research on BIOYF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOYF report →Similar companies
Peers in the same neighborhood.